rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ATRA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Atara Biotherapeutics: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceATRA
      Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
      Nov 10Yahoo FinanceATRA
      FDA accepts resubmitted application for Atara’s tab-cel therapy
      Oct 14Investing.comATRA
      Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

      THOUSAND OAKS, Calif., October 14, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel,

      Oct 14Yahoo FinanceATRA
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailATRACNTB
      Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics
      Sep 20BarchartATRA
      Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health
      Sep 10BarchartATRA
      Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares
      Sep 4Investing.comATRA
      Atara Biotherapeutics president and CEO sells $40,882 in shares
      Aug 27Investing.comATRA

      This is the newest page. Registered accounts read further back.